Premium
Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors
Author(s) -
Kyriakidis Ioannis,
Tragiannidis Athanasios,
Zündorf Ilse,
Groll Andreas H.
Publication year - 2017
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.12621
Subject(s) - alemtuzumab , abatacept , medicine , immunology , etanercept , daclizumab , ixekizumab , natalizumab , efalizumab , rituximab , adalimumab , infliximab , population , progressive multifocal leukoencephalopathy , monoclonal antibody , tumor necrosis factor alpha , psoriasis , lymphoma , psoriatic arthritis , secukinumab , antibody , environmental health , multiple sclerosis
Summary An expanding list of immunomodulatory or immunosuppressive monoclonal antibodies (mAbs) and biologic therapeutics is currently entering clinical practice, particularly in the areas of oncology, transplantation and autoimmune disorders. These agents are directed against molecules or cells involved in inflammation and immunity and may therefore be associated with serious and opportunistic infections. The purpose of this review was to critically analyse the literature on invasive fungal infections ( IFI s) occurring in association with mAbs and fusion proteins other than tumour necrosis alpha ( TNF ‐α) inhibitors, including therapeutics modulating T‐cell‐mediated pathologies (muromonab, abatacept, belatacept, ipilimumab, basiliximab, daclizumab), inducing lymphopenia (alemtuzumab), depleting CD 20+ B cells (rituximab) and interfering with various targets (anakinra, natalizumab, blodalumab, ixekizumab and others) with a focus on children, and to provide a framework of evaluating the risk for IFI s in this population.